Loading…
← CockpitCompetitor Analysis › GENB Generate Biomedicines, Inc.Open in the cockpit ↗

Generate Biomedicines, Inc.GENBCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Uses generative AI to design novel protein-based medicines across multiple disease areas.

Momentum laggard 18
Mkt cap
$1.34B
US dollars, full cap
Free float
43%
of shares outstanding
$/day
$13.5M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 6.5%
Hurdle
n/a
no reverse DCF
Next earnings
105 days
3 Mar 2027
Close · USD$10.38
1D+5.5%
1W-23.1%
1M-19.5%
3M-35.1%
6M-20.3%
YTDn/a
1Yn/a
ATR %10.8%
52w lowhigh54.2% off high

What Generate Biomedicines does

Uses generative AI to design novel protein-based medicines across multiple disease areas.

Has no approved medicine yet; income so far has come from upfront and milestone payments under partnerships such as those with Novartis and Amgen, with the rest funded by investors. Its approach is to design proteins by computer and test them in the lab, feeding results back into the models.

Products and services

  • Generative AI protein design platform
  • Pipeline in immunology, oncology and infectious disease

Customers

  • Pharma partners including Novartis

Where it sits in the supply chain

  • Health Care
  • Biotechnology
  • AI-generated protein therapeutics

What could go right

  • Novartis and other pharma partnership milestones
  • Platform validation via clinical progress

What could go wrong

  • Early-stage/pre-clinical pipeline risk
  • High R&D cash burn

Moat: narrow (data, IP / patents, process know-how). Generative AI platform for de novo protein design, backed by Flagship Pioneering and a Novartis partnership.

Headquarters: Somerville, Massachusetts, US · Founded: 2018 · Employees: 312

Named competitors

Generate Biomedicines at a glance

Size Generate Biomedicines (GENB) is a United States Health Care company (Biotechnology) with a market value of $1.34B, the 2048th largest of 3,085 United States companies the cockpit tracks. Shares closed at $10.38 on 18 Nov 2026.

Performance Over six months the shares fell 20.3%, against -20.3% for the median peer and -2.2% for the United States market (cap-weighted) — 10th highest of 20 in its peer set.

Growth Revenue grew 55.9% over the last twelve months (peer median +14.4%); the operating margin is -737.0% (peer median -16.5%).

Valuation It trades at 31.7× enterprise value to sales against a peer median of 8.4× (8th most expensive of 19).

Short interest Short interest is 7.1% of the free float (30 Oct 2026).

Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).

Relative performance

7510012515021 May 202621 Aug 202618 Nov 2026Peer median 80GENB 74
Six months, rebased to 100: Generate Biomedicines against the median of its 20 peers (local-currency closes).

Generate Biomedicines financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024
Revenuen/a$31.9M$20.5M
Revenue growth—+56%—
Gross profitn/a$18.7M$5.11M
EBITDAn/a-$222M-$182M
Net incomen/a-$203M-$174M
Free cash flown/a-$204M-$121M
Capital expendituren/a$3.51M$3.45M
Total debt$75.3M$68.5M$77.0M

Quarterly statements and history in the cockpit →

Generate Biomedicines competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%-25%0%+25%+50%NUVBTYRA6185NVAXNTLA4588TSHAANABABSI688105301207688765688739GENB6-month return →1-month return →
Up and to the right = strong over both horizons. Generate Biomedicines is the large dot.

Fundamentals: revenue growth against valuation

0%+500%+1,000%+1,500%0×250×500×750×NUVB6888066185NVAX4588TSHAABSIQURE688765URGNGENBRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Generate Biomedicines is the large dot.

Generate Biomedicines competitors and peer comparison

Head to head with its named competitors (GENB vs ABSI vs RXRX)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Generate Biomedicines GENB$1.34B-20%+56%-737%31.7×n/a
Absci ABSI$1.41B+65%-47%-9,155%835.7×n/a
Recursion Pharmaceuticals RXRX$1.76B-5%+56%-725%18.8×n/a

How Generate Biomedicines compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Generate Biomedicines against its 20 peers (data as of 18 Nov 2026)
MeasureGENBPeer medianRank in peer set
1-month return-19.5%-14.8%6th lowest of 21
6-month return-20.3%-20.3%10th highest of 20
Distance from 52-week high-54.2%-46.5%6th lowest of 21
Revenue growth (TTM)+55.9%+14.4%6th highest of 19
Operating margin-737.0%-16.5%7th lowest of 20
EV / Sales31.7×8.4×8th most expensive of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Generate Biomedicines GENBUnited States$1.34B-20%+56%-737%31.7×n/an/a
Nuvation Bio NUVBUnited States$1.34B-16%+654%-61%5.7×n/an/a
Tyra Bioscience TYRAUnited States$1.35B-41%n/an/an/an/an/a
Zhuhai Trinomab Pharmaceutical 688806.SSChina$1.32Bn/a+238%-1,196%164.8×n/an/a
CanSino Biologics 6185.HKHong Kong$1.36B-23%+36%-4%6.8×n/an/a
Novavax NVAXUnited States$1.31B-14%-61%-17%2.4×n/an/a
Intellia Therapeutics NTLAUnited States$1.37B-20%-8%-821%21.3×n/an/a
Oncolys BioPharma 4588.TJapan$1.37B+181%+1,749%-295%408.9×n/an/a
Taysha Gene Therapies TSHAUnited States$1.30B-27%-13%-2,998%170.1×n/an/a
Rapport Therapeutics RAPPUnited States$1.39B-34%n/a-838%50.1×n/an/a
AnaptysBio ANABUnited States$1.40B-22%+13%62%7.9×0.5%+25.6%
Absci ABSIUnited States$1.41B+65%-47%-9,155%835.7×n/an/a
uniQure QUREUnited States$1.42B-17%+28%-1,027%65.4×n/an/a
Nanjing Vazyme Biotech 688105.SSChina$1.42B+25%+16%-5%4.9×39.4%-2.5%
Hualan Biological Vaccine 301207.SZChina$1.25B-29%-28%-7%9.0×33.2%-13.1%
Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCRUnited States$1.44B-7%+13%-7%2.3×n/an/a
Pacific Shuanglin Bio-pharmacy 000403.SZChina$1.24B-21%+1%10%3.5×n/an/a
Wuhan Healthgen Biotechnology 688765.SSChina$1.46B-51%+90%-297%205.0×n/an/a
UroGen Pharma URGNUnited States$1.46B-1%+159%-12%6.3×n/an/a
Fujian Haixi Pharmaceuticals 2637.HKHong Kong$1.47B-32%+25%33%n/an/an/a
Liaoning Chengda Biotechnology 688739.SSChina$1.22B-14%-9%0%2.2×6.6%-7.0%

Questions

Who are Generate Biomedicines's main competitors?
Named competitors: Absci (ABSI), Recursion Pharmaceuticals (RXRX), Xaira Therapeutics (private or unlisted). The cockpit's measured peer set (industry) also includes Nuvation Bio (NUVB), Tyra Bioscience (TYRA), Zhuhai Trinomab Pharmaceutical (688806.SS), CanSino Biologics (6185.HK), Novavax (NVAX), Intellia Therapeutics (NTLA).
Is Generate Biomedicines expensive compared with its peers?
On ev / sales it trades at 31.7× against a peer median of 8.4×, 8th most expensive of 19 in its peer set.
How has Generate Biomedicines stock performed?
Over six months to 18 Nov 2026 the shares returned -20.3% against -20.3% for the median peer.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.